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Abstract: Melatonin (MLT) is a recently discovered phytochemical in wine, but its influence on
physiological MLT levels is still unknown. This study aimed at evaluating variations, in serum and
saliva, of MLT concentrations after the intake of MLT-enriched red wine. Twelve healthy volunteers
were recruited to receive 125 mL of red wine naturally lacking of MLT (placebo, PLC), or the same
wine enriched with MLT (MLT+). A physiological steady decline of serum MLT was observed from
baseline up to 90 min, for both wines. After PLC intake, the decrease was significantly faster than the
one occurring after MLT+ wine, which thus delayed the drop down of serum MLT with a plateau at
30–60 min. Salivary MLT levels slightly peaked at 45 min after MLT+ wine intake, without statistical
significance. Therefore, the intake of a glass of MLT-enriched red wine changed serum levels of
the indoleamine, supporting the role of wine MLT in counteracting the physiological decline of the
hormone into the bloodstream.
Keywords: Mediterranean diet; indoleamines; nutraceuticals; functional foods
1. Introduction
Although the paradigm of red wine health-promoting effects has been largely attributed to
polyphenols, in the last decade, a new molecule enriched this scenario: melatonin (MLT) [1]. Dietary
MLT may, indeed, have direct beneficial effects and maximize the biological activities of micronutrients
(vitamins and minerals) and other phytochemicals present in plant foods [2,3].
Mercolini and colleagues [4,5] found 0.5 ng mL−1 of MLT in Sangiovese red wine, and 0.6 and
0.4 ng mL−1 in Albana and Trebbiano white wines, respectively. Stege and co-workers reported MLT
at 0.16, 0.24 and 0.32 ng mL−1 in Chardonnay, Malbec and Cabernet Sauvignon wines, respectively [6].
Results from our group showed the levels of MLT in Groppello and Merlot wines varied between 5.2
and 8.1 ng mL−1, depending on the agrochemical treatments [7]. Other authors reported even much
higher MLT concentrations, up to 130 and 420 ng mL−1, in red and white wines (Cabernet Sauvignon,
Merlot, Syrah, Tempranillo, Tintilla de Rota, Petit Verdot, Prieto Picudo and Palomino Fino) [8].
Again, in a screening of Italian mono- and polyvarietal red, white and dessert wines from different
geographical areas, we measured MLT at concentrations around or less than 0.5 ng mL−1 [9]. However,
the presence of this indoleamine in wine is not always the rule: MLT in grape (cv. Malbec) berry skins
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was detected within the range 120–160 ng g−1, but it was no more present in the experimental wines
(produced from the same grapes); here, a MLT isomer was identified, in the range 18–24 ng mL−1 [10].
In another study, MLT was found in berry skin (440 ng g−1), but not in the experimental and commercial
wines, whereas a MLT isomer was measured in wine (from 60 to 211 ng mL−1), but not in berry
skins [11]. This great and unpredictable variability of results is likely due to factors that may influence
the biosynthesis of MLT in grapes and, consequently, the levels of this indoleamine in wine, as well
as factors related to vinification. Among the others, genetic traits of cultivars, phenological stages of
development, agrochemical treatments, climatic and agro-meteorological conditions and winemaking
procedures could play a pivotal role [12].
To complicate the picture further, oral bioavailability may affect the health-promoting effects
of dietary phytochemicals [13], including MLT, as it relies on the biotransformation system of the
individual, on the chemical structure of each compound, as well as on the high complexity of the food
matrix, as the red wine actually is.
Although oral availability of red wine polyphenols has been investigated [14,15], no information
is currently available on oral bioavailability of MLT after drinking a glass of red wine containing this
indoleamine. Noteworthy, differently from polyphenols, which are plant-exclusive metabolites reliably
detectable in humans, the levels of exogenous MLT coming from foods (usually in the order of ng/g or
ng/mL) cannot be distinguished unfailingly from the levels of MLT endogenously produced. Indeed,
there is still a lack of knowledge about oral bioavailability of dietary MLT from red wine, a complex
food matrix, though its pharmacokinetics as dietary supplement (at much higher doses) in forms of
capsules, spray or gel has been known for decades [16,17]. The complexity of food matrix, in turn,
could strongly influence absorption of bioactive metabolites, including MLT, present in foods, thus
affecting the biological significance of the molecule.
This study aimed at investigating, for the first time, the levels of MLT in serum and saliva soon
after the intake of a MLT-enriched red wine.
2. Results
Fourteen individuals were contacted, but two of them refused for personal reasons (no wine
drinking) (Figure 1).Molecules 2018, 23, x FOR PEER REVIEW  3 of 10 
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Table 1. Demographics, anthropometric characteristics and dietary habits of participants (n = 12). 
No. Gender 
Age 
(Years) 
Height 
(cm) 
Weight 
(Kg) 
BMI  
(Kg m−2) 
Fruits 
(Servings/Day) 
Vegetables 
(Servings/Day) 
Wine 
1 M 22 171 65 22.2 0.5 0.5 <2 glasses/week 
2 M 25 178 66 20.8 1 1 <2 glasses/week 
3 M 43 179 89 27.8 0.5 0.5 2–7 glasses/week 
4 F 24 164 52 19.3 2 2 1 glass/day 
5 M 24 180 74 22.8 2 2 0 
6 F 22 165 52 19 3 3 2–7 glasses/week 
7 F 24 170 61 21 1 2 0 
8 M 21 178 64 20.2 2 2 0 
9 F 29 165 55 20.2 3 3 1 glass/day 
10 F 23 157 48 19.5 1 1 0 
11 M 24 178 76 24 2.5 0.5 0 
12 M 29 185 74 21.6 0.5 0.5 1.5 glass/day 
Mean 25.8 172.5 64.6 21.3 1.9 2  
SD 5.9 8.4 12 2.5 0.8 0.7  
2.1. Melatonin Concentrations in Serum and Saliva 
After the administration of wines, a significant, steady decline of serum MLT was observed from 
baseline up to 90 min for both MLT+ and PLC wines, despite following different kinetics (Figure 2A–
C). Patient No. 3, in particular, showed a strong peak of MLT at 60 min, after MLT+ wine intake 
(Figure 2A), not detectable after PLC (Figure 2B). The administration of MLT+ wine delayed the drop 
down of serum MLT producing a plateau at 30 and 60 min (8.6 ± 1.4 pg mL−1 and 8.7 ± 2.2 pg mL−1, 
respectively), no more detectable at 90 min (Figure 2C, ANOVA, p ≤ 0.05). Consistently, when MLT 
plasma concentrations obtained at different time points were corrected for individual baseline MLT 
concentrations, the plateau was confirmed. At 30 and 60 min, MLT+ wine produced a decrease of the 
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Thus, twelve volunteers were recruited (seven males and five females; mean age: 25.8 ± 5.9 years;
mean BMI: 21.3 ± 2.5 kg m−2). Demographic and anthropometric characteristics of each volunteer and
dietary habits are detailed in Table 1. Eleven out of twelve volunteers completed the study, with high
compliance. Only female participant No. 10 dropped out because of a lipothymic episode during the
blood withdrawal at baseline.
Table 1. Demographics, anthropometric characteristics and dietary habits of participants (n = 12).
No. Gender Age(Years)
Height
(cm)
Weight
(Kg)
BMI
(Kg m−2)
Fruits
(Servings/Day)
Vegetables
(Servings/Day) Wine
1 M 22 171 65 22.2 0.5 0.5 <2 glasses/week
2 M 25 178 66 20.8 1 1 <2 glasses/week
3 M 43 179 89 27.8 0.5 0.5 2–7 glasses/week
4 F 24 164 52 19.3 2 2 1 glass/day
5 M 24 180 74 22.8 2 2 0
6 F 22 165 52 19 3 3 2–7 glasses/week
7 F 24 170 61 21 1 2 0
8 M 21 178 64 20.2 2 2 0
9 F 29 165 55 20.2 3 3 1 glass/day
10 F 23 157 48 19.5 1 1 0
11 M 24 178 76 24 2.5 0.5 0
12 M 29 185 74 21.6 0.5 0.5 1.5 glass/day
Mean 25.8 172.5 64.6 21.3 1.9 2
SD 5.9 8.4 12 2.5 0.8 0.7
2.1. Melatonin Concentrations in Serum and Saliva
After the administration of wines, a significant, steady decline of serum MLT was observed from
baseline up to 90 min for both MLT+ and PLC wines, despite following different kinetics (Figure 2A–C).
Patient No. 3, in particular, showed a strong peak of MLT at 60 min, after MLT+ wine intake (Figure 2A),
not detectable after PLC (Figure 2B). The administration of MLT+ wine delayed the drop down of
serum MLT producing a plateau at 30 and 60 min (8.6 ± 1.4 pg mL−1 and 8.7 ± 2.2 pg mL−1,
respectively), no more detectable at 90 min (Figure 2C, ANOVA, p ≤ 0.05). Consistently, when MLT
plasma concentrations obtained at different time points were corrected for individual baseline MLT
concentrations, the plateau was confirmed. At 30 and 60 min, MLT+ wine produced a decrease of the
indoleamine equal to −1.7 ± 1 pg mL−1 (11%) and −1.6 ± 2 pg mL−1 (14%), respectively, whilst PLC
wine produced a decrease equal to −3.3 ± 1.3 pg mL−1 (20%) and −4.5 ± 1.3 pg mL−1 (37%).
The maximum concentration (Cmax) of MLT was 8.7 ± 2.2 pg mL−1, achieved 60 min (Tmax)
after the intake of red wine enriched with this molecule, while, for PLC, Cmax was 6.7 ± 0.6 pg mL−1
at 30 min (tmax). The area under the curve (AUC) was 745 ± 88 pg min−1 per mL for PLC-wine
and 993 ± 162 pg min−1 per mL for MLT+ wine. These differences were not statistically significant
(two-sample t-test).
Salivary levels of MLT slightly peaked at 45 min after MLT+ wine intake, though without a
statistical significance, returning to levels closer to the PLC at 120 min (Figure 2D).
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trial, more frequently after MLT+ wine intake (Table 2). 
  
Figure 2. (A,B) Time-course of the serum melatonin levels in each of the healthy volunteers from
0 min to 90 min after administration of red wine (A) without melatonin (placebo, PLC) or (B) the same
wine fortified with melatonin (MLT). (C) Time-course of the serum melatonin mean levels in healthy
volunteers (n = 11) from 0 min to 90 min after administration of red wine without melatonin (PLC)
or the same wine fortified with melatonin (MLT). Error bars represent the standard error of the mean
(SEM). Statistical analysis: Different lower case or capital letters indicate differences within group and
between groups, respectively (p ≤ 0.05, ANOVA, Tukey’s HSD test). (D) Time-course of the salivary
melatonin mean levels in healthy volunteers (n = 11) from 0 min to 120 min after administration of red
wine without melatonin (PLC) or the same wine fortified with melatonin (MLT). Error bars represent
the standard error of the mean (SEM). Statistical analysis: Different lower case or capital letters indicate
differences within group and between groups, respectively (p ≤ 0.05, ANOVA, Tukey’s HSD test).
2.2. Adverse Effects
Among side effects, sleepiness was the most frequently adverse event complained during the
trial, more frequently after MLT+ wine intake (Table 2).
Table 2. Side effects and adverse events reported by the volunteers (n = 11).
Wine Loss of Concentration Numbness Sleepiness Headache Gastric Pain Others
Melatonin 2 0 8 1 1 3 *
Placebo 2 1 6 1 2 0
* Flush, n = 2; tiredness, n = 1.
3. Discussion
In human, data on dietary MLT absorption are still scant, being currently documented just in two
clinical trials [18,19]. Maldonado reported that, in seven healthy volunteers, serum MLT significantly
increased 45 min after drinking beer containing MLT (total MLT ingested 112 ng for men and 56 ng for
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women) [19]. Sae-Teaw et al. [18] showed that, in 12 healthy male volunteers, serum MLT concentration
peaked 120 min after fruit consumption (total MLT ingested 302 ng, 150 ng and 8.9 ng for pineapple,
orange and banana, respectively).
To the best of our knowledge, to date, the effect of a glass of red wine intake on MLT levels
has never been investigated, despite the overwhelming interest of research on this beverage and this
molecule. Here, we aimed at clarifying the issue, by using a MLT-enriched wine containing the same
amount of MLT naturally found in wine to reproduce, at the most, a real intake condition. We applied
a highly accurate and reliable study design, i.e., a randomized, crossover, controlled clinical trial,
which represents the highest level of evidence in clinical experimental research [20].
From our findings, although we could not distinguish unfailingly between endogenous and
exogenous MLT and given the low dose contained in our wine and the sensitivity of LC/MS method
applied as well, we found minor changes in serum MLT concentrations, as a reduced drop of the
molecule over time. We can speculate that MLT+ wine may counteract the physiological decline of
serum MLT during the morning. This physiological decline is consistent with previous literature
reporting a decrease of serum MLT in volunteers from 10.98 pg mL−1 before 09.00 to 1.96 pg mL−1 after
11.00 [21]. The time points reflecting red wine MLT systemic absorption are consistent with the previous
study on MLT in beer [19] and are slightly different from the ones reported by Sae-Teaw et al. [18]
on MLT in fruits, which peaked at 120 min. The differences amongst the food matrixes could have
affected the absorption rate: the presence of ethanol, as in our case, could have contributed, due to its
solvent nature, to enhance the permeability of mucosal membranes of the gastrointestinal tract [22].
Moreover, previous studies [18,19] reported higher serum levels of MLT after food intake than ours.
The different method used for serum analysis can explain, at least in part, these differences. In those
studies [18,19], the MLT levels were determined by enzyme-linked immunosorbent (ELISA) assay.
Here, we measured the serum MLT concentration in humans by the more accurate and reliable LC/MS
technique, which overcomes the methodological issue related to ELISA cross-reactivity with unspecific
molecules, such as MLT isomers and other indoleamines. Although this analytical approach is more
precise than previously used ones, a further operational improvement would arise using LC-MS/MS
technique allowing to detect MLT and respective metabolites more and more precisely. Besides the
methodological issue, differences among studies can be ascribed to the MLT produced by the epithelial
tissues of gastrointestinal tract and released within blood circulation, which can confound the real
amount of dietary MLT absorbed [19,23]. The presence of putative and yet unidentified compounds
(such as MLT precursors or phytochemicals) in the beer and fruits could also stimulate the biosynthesis
of endogenous MLT, further complicating the picture [19].
On the other hand, we found a slight MLT peak in saliva after 45 min from MLT+ wine intake.
We hypothesize that it could be due to the topical presence of wine MLT rather than coming from
bloodstream. Food MLT, indeed, may bind the oral mucosa surface, similar to what occurs in presence
of red wine polyphenols, although the precise mechanisms are still unknown [24]. Topical MLT may be
in turn systemically absorbed via transmucosal absorption but at really very low level, as occurs with
drugs [25]. MLT receptors are represented in the oral mucosa possibly to mediate specific biological
activities [26]. In any case, we have to take into account that the topical presence of MLT can act as a
confounder when assessing salivary levels of the molecule after food intake. This is of great relevance
considering the low dose contained in wine and the even lower dose systemically absorbed after
the ingestion.
The limitations of our study, however, impede conclusive dissertations. The major drawbacks
include the small sample size and the need of verifying the presence, in serum and saliva, of red
wine’s MLT isomers—possibly different from the endogenous ones. Moreover, future research should
focus on considering the measurement of MLT 24-h rhythms that include nocturnal levels of the
molecule, which can contribute to better elucidate how wine can affect individual’s circadian rhythm
of endogenous MLT.
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4. Materials and Methods
4.1. Volunteers
Participants included female and male young individuals (20–45 years of age), healthy,
with normal weight (Body Mass Index, BMI, 18.5–25.0 kg m−2) who voluntarily accepted to join
the study. All volunteers provided their written informed consent, signing a letter of agreement.
For each individual, demographics, anthropometric characteristics and dietary habits were recorded,
including consumption per day/week of alcoholic beverages, fruits, vegetables, tea and coffee; the level
of physical activity (min per week); and the smoking habit. Among clinicians and students of the
Departments involved in the study, individuals were considered eligible and were contacted. Exclusion
criteria were: pregnancy and lactation for women; supplementation with MLT and/or any other dietary
supplement (vitamins, antioxidants, botanicals, phytochemicals); systemic and chronic-degenerative
diseases; abnormal hematological parameters; heavy smoking (more than 10 cigarettes/day) and
heavy alcohol drinking (more than 8 standard drinks per week for women and more than 15 standards
drinks per week for men); and high-intensity physical activity. None of the volunteers was taking any
pharmacological treatment.
4.2. Ethical Approval
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki
and it received the ethics approval by the Institutional Ethical Committee (Università degli Studi di
Milano, approved 10 July 2014).
4.3. Experimental Overview and Study Design
The study was designed as triple-blind clinical trial, where participants, care providers, and
investigators assessing outcomes where not informed on assignments to interventions. It was also
randomized, crossover, placebo-controlled and registered at www.clinicaltrial.gov (ID: NCT02767102).
All phases of the trial were performed at Clinica Odontoiatrica Università degli Studi di Milano,
Polo San Paolo, where data were collected and analyzed (date range for participant recruitment: from
10 July 2014 to 17 July 2014; date range for performing the trial and follow-up: from 21 July 2014
to 31 July 2014). At baseline, demographics and anthropometric characteristics, dietary habits and
physical conditions of the participants were recorded, and the inclusion/exclusion criteria were
reviewed. Then, volunteers were randomized to receive one glass (125 mL) of red wine in two different
experimental days, according to one of the following sequences (Figure 3): (i) sequence A—on first
experimental day, the participant received placebo (PLC) red wine, followed by 1-week wash-out, and,
on second experimental day, the same participant received MLT enriched (MLT+) red wine; and (ii)
sequence B—on the first experimental day, the participant received MLT+ wine, followed by 1-week
wash-out, and, on the second experimental day, the same participant received PLC wine.Molecules 2018, 23, x FOR PEER REVIEW  7 of 10 
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A simple randomization method was applied. The randomization list was prepared using
an online tool (http://graphpad.com/quickcalcs/randomise1.cfm) and allocation concealment was
ensured because the person who generated the randomization list and assigned the volunteers to the
two arms was not involved in evaluating eligibility of individuals and their enrolment. One of the
authors (E.V.) administered the wine glass to volunteers, who were instructed to consume wine within
1–5 min, immediately after the first basal blood and saliva collection performed at 08:30. Both wines
(with and without MLT) were administered in two identical glasses and they had the same color and
flavor. Further blood withdrawals were collected at 30, 60 and 90 min, whereas further saliva samples
were collected, via unstimulated spitting method [24], at 45 and 120 min after wine administration.
4.4. Dietary Control
A dietary control was performed the 24 h before the beginning of the trial and during the
experimental day: individuals were required to avoid the consumption of alcoholic beverages, extra
virgin olive oil, coffee, tea, nuts, rice, legumes, fruits, dairy products and mushrooms. Volunteers
fasted overnight and came to the laboratory at 08:00, where they consumed a light MLT free breakfast
(40 g of non-whole biscuits with 125 mL of warm water).
4.5. Placebo and MLT Enriched Red Wines
Placebo red wine (PLC wine) was a red wine naturally lacking of MLT, called Rosso di
Marco (cv. Pignatello, Terre Siciliane IGT), which was formerly screened in our previous work on
the MLT content in Sicilian red, white and dessert wines [9]. The farm De Bartoli (Pantelleria,
Italy) kindly provided this wine. MLT enriched red wine (MLT+ wine) was the same red
wine fortified with 10 ng mL−1 MLT: Briefly, 125 µL of an aqueous solution, containing MLT
(N-Acetyl-5-methoxytryptamine, ≥99.5%, purchased from Sigma-Aldrich®, Saint Louis, MO, USA) at
a concentration of 10 µg mL−1, was added to the wine to reach the final concentration. The enrichment
corresponded to an intake of 1.25 µg of MLT per glass. This amount of MLT was selected because in
agreement with the mean levels of MLT detectable in wines according to previous studies [6–8,27].
All analyses of wine MLT were carried out as already reported [9]. An investigator, not involved in the
clinical trial and not aware of the randomization list, added the molecule. The two bottles, containing
PLC or MLT+ red wines, were identical and just coded with 1 (MLT) or 2 (PLC). Only two members in
the research team, M.I. and G.L., who did not participate in any of clinical phase or data collection or
data analyses, were aware of the codes.
4.6. Melatonin Concentrations in Serum and Saliva
Serum MLT levels (primary outcome) were determined on blinded samples following the
method described by Wang et al. [28] with slight modifications. We used a high performance liquid
chromatography (Ultimate 3000, Dionex, Sunnyvale, CA, USA) coupled to a triple quadrupole mass
spectrometer (ABSciex QTrap 3200, ABSciex, Milan, Italy) (LC-MS), using N-acetyltryptamine as
internal standard. We preferred the solid-phase extraction instead of the liquid–liquid extraction
with dichloromethane [28] to avoid the difficult transfer with a tip of an organic phase below the
aqueous one. After pre-analytical processing, samples were injected in a ZORBAX Eclipse dsDNA
Analysis (Agilent; Santa Clara, CA, USA) (2.1 mm i.d. × 75 mm, 3.5 µm) at 40 ◦C. The flow-rate was
0.4 mL min−1 and the samples were eluted by a gradient between (A) ammonium formate 2 mM
with 0.1% formic acid, and (B) acetonitrile (30% B for 1 min, 30–60% B in 3 min, 60–99% B in 0.1 min,
99% B for 1 min, 99–30% B in 0.1 min, post run per 0.9 min). Total run time 6.2 min. The multiple
reaction monitoring (MRM) technique was used for the quantification of MLT in serum samples,
selecting the optimized fragmentation m/z 233→ 174, declustering potential (DP) 26 V and collision
energy (CE) 20 V for MLT, and m/z 203→ 144, DP 15 V and CE 20 V for N-acetyltryptamine (internal
standard). Salivary MLT was measured by ELISA kit (BTB-E1013Hu, Human Melatonin, MT ELISA
Kit, Li StarFISH S.r.l.; Milan, Italy), following manufacturer instructions.
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Maximum plasma concentrations (Cmax) and times to achieve maximum plasma concentrations
(tmax) were obtained directly by serum concentration time profile. The area under the plasma
concentration–time curve (AUC) was determined according to the linear trapezoidal rule.
4.7. Volunteers’ Compliance and Adverse Effects
Volunteers consumed the glass of wine under the direct, visual supervision of the clinical
investigator, who also recorded the exact time required to each participant to drink the glass of
wine (from 1 to 5 min). During each experimental day, volunteers were instructed to record any
side effect due to the wine drinking, using an ad hoc questionnaire. They were asked to indicate,
in particular, loss of concentration, numbness, sleepiness and drowsiness, headache, gastric pain or
any other adverse event.
4.8. Statistical Analysis
The sample size (n = 14) to assure at least the 80% statistical power was calculated, using an
online statistical software (http://www.sample-size.net/means-effect-size/) and considering the
20% of dropouts. The calculation was based on the effect size and standard deviations observed
from previous literature concerning MLT serum concentration after the intake of beverages containing
MLT [18,19]. Statistical analysis was carried out on blinded data using OriginPro® software (version 8.0,
Northampton, MA, USA), and the results are represented as means with their standard errors
(SEM). Data were analyzed using a per protocol approach. Within group and between groups
comparisons were assessed by the two-way analysis of variance (ANOVA) for repeated measurements
within participants. Significant within group and between groups differences were accepted at
p ≤ 0.05 and comparison among means was determined according to the Tukey’s honestly significant
difference (HSD) test. Two-sample t-test was calculated to assess differences of Cmax, tmax and AUC
between groups.
5. Conclusions
Our results showed that, after the acute administration of a glass of MLT+ wine, levels of this
indoleamine in the bloodstream change, peaking at 60 min after the intake. Noteworthy, the absorbed
dietary MLT significantly counteracted the physiological decrease of the endogenous MLT in the serum.
Salivary MLT slightly peaked at 45 min after MLT+ wine intake, probably because of a topical effect.
Further studies are needed to elucidate the biological significance of dietary MLT in humans.
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